Advances in surgery
-
Based on the experience to date with IPMNs, the approach to patients remains relatively complex. A meticulous and careful approach to diagnosis, oncologic risk assessment, operative planning, and surveillance is needed to adequately address these lesions. Indications for resection in patients with IPMN are (1) cancer, (2) cancer prevention in patients at high risk for malignant transformation, and (3) management of symptoms. ⋯ Although new data continue to clarify how and when to approach IPMNs with segmental or total pancreatic resection, many questions remain unanswered. Continued efforts to uncover a more accurate natural history and behavior for IPMN continue to fill the gaps in our current understanding and practice. In the meantime, it is critical to educate and frequently restratify oncologic risk in patients based on optimal and timely data (history and physical and radiographic, endoscopic, and cytopathologic results) and rigorous follow-up to guide patients in reaching a decision of whether and when to undergo IPMN resection.
-
Wrong-site surgery happens frequently enough that it is a significant risk for many surgeons during their professional careers. But it is an event that should never happen. Most wrong-site surgery is wrong-side surgery, followed by wrong-digit and wrong-vertebral-level surgery. ⋯ Junior members of the operating room team must be made comfortable about speaking up if concerned. During spinal surgery, the vertebral level needs to be confirmed radiographically. Wrong-site surgical problems can occur after an operation if accurate information is not provided to accompany the specimen or if leftover labels from a previous patient are used to identify the specimen.
-
Advances in surgery · Jan 2008
ReviewDecreasing the pancreatic leak rate after pancreaticoduodenectomy.
Although pancreaticoduodenectomy has become a safe and effective procedure for benign and malignant pancreatic diseases in recent years, leakage of pancreaticoenteric anastomosis still remains a major cause of morbidity and even mortality. Various methods have been used to prevent pancreatic fistula with either pharmacologic or technical approaches. Based on meta-analysis of results from European and American trials, prophylactic use of octreotide to inhibit pancreatic secretion cannot be recommended for routine use in pancreaticoduodenectomy. ⋯ Use of PG instead of PJ anastomosis, internal stenting of PJ anastomosis, pancreatic duct occlusion, and fibrin glue have not been shown to be effective in reducing pancreatic leakage rate after pancreaticoduodenectomy. One randomized trial recently showed significant reduction of pancreatic leakage rate using an external diverting stent after PJ anastomosis, and another randomized trial showed significant reduction in PJ anastomosis leakage using the binding PJ anastomosis technique. Nonetheless, further high-quality randomized controlled trials are needed to evaluate the benefit of these technical modifications in decreasing the pancreatic leakage rate after pancreaticoduodenectomy.
-
Advances in surgery · Jan 2008
ReviewThe global health workforce shortage: role of surgeons and other providers.
The debate over the status of the physician workforce seems to be concluded. It now is clear that a shortage of physicians exists and is likely to worsen. In retrospect it seems obvious that a static annual production of physicians, coupled with a population growth of 25 million persons each decade, would result in a progressively lower physician to population ratio. ⋯ Three of the 12 points reflected significant change from past positions. They are a call for a 30% increase in physicians graduated by United States allopathic medical schools and an increase in residency positions now limited by the BBA of 1997. The recommendation that students make personal specialty choices reversed the prior recommendation that a majority of students enter primary care practice.
-
Glycemic control clearly improves outcome in critically ill patients. Remaining questions are how tight the control must be to obtain the most benefit without increasing the risk for severe hypoglycemia, and whether an acuity level exists in which this benefit is not clearly visualized. In other words, is this benefit only seen in severely ill patients? The authors believe that clinical trials with ICU lengths of stay of 3 days or less make showing a clinical benefit difficult. ⋯ Finally, the issue remains of how to obtain a TGC in the 80 to 110 mg/dL range without achieving a less-than-acceptable incidence of hypoglycemia. The answer may well lie with the introduction of continuous glucose monitors that will allow measurements to be obtained every 15 to 30 minutes without introducing an increased workload to the nursing staff. Many of these devices, such as the Optiscanner, which measures plasma glucose continuously, are on the horizon and should be approved by the FDA in 2008.